Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Angiotensin Receptor Blockers (ARBs) Market?

The market for angiotensin receptor blockers (arbs) has seen consistent growth over the past few years. The industry, currently valued at $8.51 billion in 2024, is projected to increase to $8.78 billion in 2025, boasting a compound annual growth rate (CAGR) of 3.1%. This growth during the historical period is consequent of several factors including the widespread hypertension situation, clinical effectiveness, a high prevalence of cardiovascular diseases, renal safeguarding, clinical guidelines, the use of ARBs as a primary treatment option, and cost-effectiveness.

The market size of angiotensin receptor blockers (arbs) is anticipated to experience consistent expansion in the coming years, with projections indicating a growth to “$10.52 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The predicted growth in this period can be linked to precision medicine methods, prioritization of combination therapies, worldwide market expansion, treatment tactics based on biomarkers, government schemes and increased understanding of hypertension. Key trends to watch during this forecast period encompass the incorporation of telemedicine, investment in research and development, the competition from generics and patent expirations, digital health solutions to ensure medication adherence, and competition from biosimilars.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

Which Key Factors Are Fueling Growth In The Angiotensin Receptor Blockers (ARBs) Market?

The surge in cardiovascular disease incidents is predicted to fuel the advancement of the angiotensin receptor blockers market. Conditions impacting the heart or blood vessels are classified as cardiovascular diseases (CVD). They often coincide with the evolution of fatty residue in the arteries (atherosclerosis), accelerating the probability of blood clots. Angiotensin receptor blockers alleviate blood pressure and enhance the heart’s blood pumping capability by facilitating the relaxation of veins and arteries, thereby reducing the likelihood of cardiovascular diseases. For example, the American College of Cardiology, a US-based healthcare professional institution, projected in August 2022 that the prevalence of cardiovascular risk determinants and diseases will significantly escalate in the United States towards 2060. Hence, the escalating prevalence of cardiovascular diseases is propelling the angiotensin receptor blockers market’s expansion.

What Segmentation Insights Are Provided In The Angiotensin Receptor Blockers (ARBs) Market Research?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

Which Notable Trends Are Transforming The Angiotensin Receptor Blockers (ARBs) Market Outlook?

Leading businesses operating in the angiotensin receptor blocker market are creating advanced products like angiotensin receptor neprilysin inhibitors, to broaden treatment possibilities and enhance patient outcomes in cardiovascular diseases. Medications known as angiotensin receptor neprilysin inhibitors (ARNIs) are utilized in heart failure treatment. For example, in January 2023, Glenmark Pharmaceuticals, a pharmaceutical firm based in India, introduced sacubitril + valsartan tablets tailored for heart failure treatment, specifically for heart failure with reduced ejection fraction (HFrEF). This combination is categorized as ARNI (angiotensin receptor neprilysin inhibitors). Sacubitril enhances the natriuretic peptide system, which helps in fluid overload relief and blood vessel expansion, while valsartan inhibits the renin-angiotensin system (RAS) to decrease blood pressure and reduce stress on the heart. When combined, these effectively alleviate heart failure symptoms, decrease the risk of cardiovascular death, and lower hospitalization rates due to heart failure. These products are sold under the brand name Sacu V.

Who Are The Major Stakeholders Operating In The Angiotensin Receptor Blockers (ARBs) Market?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Angiotensin Receptor Blockers (ARBs) Market?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model